TICKERNERD
Menu
CTKBCTKBHealthcare · Medical Devices

CTKB Stock Forecast: Cytek Biosciences, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$5.36
+0.37% on the day

The 4 Wall Street analysts covering Cytek Biosciences, Inc. hold a median 12-month price target of $5 — -6.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$699.3M
Ticker Nerd rank
69 / 100
Median analyst target
$5.00
Analysts covering
4
Revenue$48.1M+5.6% y/y
Operating income−$11.4M
Net income−$12.2M
Free cash flow−$877K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.7%
1M
+16.0%
YTD
+6.1%
1Y
+37.4%
From 52W high
−12.0%
From 52W low
+59.8%
$3.36
$6.09
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CTKB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cytek Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
69 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Volatility
79
Momentum
69
Value
66
Issuance
58
Quality
54
Size
49
Revisions
44
Growth
37

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (37): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTKB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTKB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.00$4.00$5.00$6.00$7.00$8.00Jan 26Apr 26Jul 26Oct 26CTKBHigh $7.50Median $5.00Low $4.75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
2 Buy2 Hold0 Sell
Low $4.75Median $5.00High $7.50

The green dot is the last close — the median target sits −6.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 May 2026Stephens & Co.MaintainsOverweight$5.50 → $4.75
12 May 2026Morgan StanleyMaintainsEqual-Weight$6.00 → $5.50
8 Jan 2026TD CowenMaintainsBuy—
11 Nov 2025Piper SandlerMaintainsOverweight—
28 May 2025Morgan StanleyMaintainsEqual-Weight—
12 May 2025Goldman SachsMaintainsSell—
19 Mar 2025Stephens & Co.ReiteratesOverweight—
4 Mar 2025Piper SandlerMaintainsOverweight—
11 Nov 2024Piper SandlerMaintainsOverweight—
13 Aug 2024Piper SandlerMaintainsOverweight—
13 May 2024Piper SandlerMaintainsOverweight—
6 Mar 2024Piper SandlerMaintainsOverweight—
29 Feb 2024Goldman SachsMaintainsBuy—
14 Dec 2023Stephens & Co.InitiatesOverweight—
9 Nov 2023Morgan StanleyMaintainsEqual-Weight—
24 Oct 2023Morgan StanleyMaintainsEqual-Weight—
16 Oct 2023Piper SandlerMaintainsOverweight—
19 July 2023Raymond JamesInitiatesMarket Perform—
11 May 2023Morgan StanleyMaintainsEqual-Weight—
10 May 2023Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTKB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CTKB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Cytek Biosciences, Inc. returned +37.4% against +16.2% for the S&P 500, dividends included.

CTKB vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26CTKBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CTKB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Cytek Biosciences, Inc. (CTKB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
374.5×

Cheaper than 2% of US stocks

Price / sales
3.3×

Cheaper than 37% of US stocks

Price / book
2.1×

Cheaper than 42% of US stocks

EV / EBITDA
−11.7×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
5.6%

Higher than 40% of US stocks

Earnings growth (YoY)
5.6%

Higher than 42% of US stocks

Gross margin
58.9%

Higher than 72% of US stocks

Operating margin
−29.5%

Higher than 19% of US stocks

Net margin
−39.0%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−23.0%

Higher than 30% of US stocks

Return on assets
−6.3%

Higher than 30% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cytek Biosciences, Inc. (CTKB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cytek Biosciences, Inc. has a market value of $699.3M and an enterprise value of $463.8M.

  • Revenue in the twelve months to 30 June 2026: $206.7M. The latest quarter grew 5.6% year on year.

  • Net income over the same four quarters: −$80.6M, a −39.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.62.

  • Free cash flow in the twelve months to 30 June 2026: −$12.2M.

  • Cytek Biosciences, Inc. spent $63K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 130.0M.

  • Trailing P/E: 374.5×; forward P/E: 74.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cytek Biosciences, Inc. employs 682 people — $303K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

CTKB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CTKBCytek Biosciences, Inc.$699.3M
69
PACBPacific Biosciences of California, Inc.$694.6M
49
AVRAnteris Technologies Global Corp.$644.6M
20
VREXVarex Imaging Corp.$774.3M
83
INMDInMode Ltd.$809.3M
75
AHCOAdaptHealth Corp.$824.3M
44
SIBNSI-BONE, Inc.$833.0M
73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cytek Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTKB news & analysis

Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool

GlobeNewsWire · 23 Sept 2026positive

Cytek Biosciences expanded its Cytek Cloud digital ecosystem with a new Cloud Analysis tool, creating what the company describes as the industry's first end-to-end flow cytometry platform. The announcement extends the company's cloud-based digital capabilities.

Why it matters — The new Cloud Analysis tool strengthens Cytek's digital ecosystem and positions its flow cytometry platform as more integrated and end-to-end, which could appeal to existing and potential customers.

Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?

Zacks Investment Research · 17 Sept 2026neutral

Zacks Investment Research reports that recent movements in the options market for Cytek Biosciences (CTKB) stock may indicate analysts and investors are anticipating a potential price spike. The article advises investors to pay close attention to the stock based on these options-market signals.

Why it matters — A CTKB watcher would care because unusual options-market activity can signal shifts in investor sentiment and expectations about the stock's upcoming direction.

Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Cytek Biosciences presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with the event transcript now available via Seeking Alpha. The presentation covered Cytek's engagement at the conference.

Why it matters — A presentation at a major investor conference gives CTKB watchers visibility into how management is communicating the company's position to institutional investors.

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

GlobeNewsWire · 3 Sept 2026neutral

Cytek Biosciences will showcase its spectral flow cytometry solutions at the ESCCA 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course, this fall. The company is highlighting the expanding role of spectral flow cytometry in clinical research as laboratories seek deeper cellular insights and streamlined cell analysis.

Why it matters — A CTKB watcher would care because the company's participation in these leading clinical cytometry events signals its focus on growing its presence and visibility in the clinical research market for spectral flow cytometry.

FAQ

Frequently asked questions about CTKB stock

What is the CTKB stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Cytek Biosciences, Inc. have a median 12-month price target of $5, with estimates ranging from $4.75 to $7.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTKB stock a buy right now?

Of the 4 analysts covering Cytek Biosciences, Inc., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cytek Biosciences, Inc. 69 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTKB?

As at 8 Oct 2026, Cytek Biosciences, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will CTKB stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies -6.7% from the last close, and Ticker Nerd's factor model ranks Cytek Biosciences, Inc. 69 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTKB stock forecast for 2030?

No analyst covering Cytek Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTKB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.75 to $7.5 over the next 12 months.

How has CTKB stock performed over the past year?

Cytek Biosciences, Inc. returned +37.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cytek Biosciences, Inc. do?

Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications.

What is the latest news on CTKB?

The most recent item we track (GlobeNewsWire, 23 Sept 2026): "Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool". Cytek Biosciences expanded its Cytek Cloud digital ecosystem with a new Cloud Analysis tool, creating what the company describes as the industry's first end-to-end flow cytometry platform. The announcement extends the company's cloud-based digital capabilities.

Company

About Cytek Biosciences, Inc.

Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications. The company’s portfolio centers on its Full Spectrum Profiling technology, which supports high-resolution, high-content, and high-sensitivity analysis of single cells. Its current product lineup includes the Aurora and Northern Lights cell analyzers, the Aurora CS cell sorter, and related integrated tools designed to help researchers study complex biological samples. Cytek Biosciences also offers conventional flow and image-based flow cytometry products through its acquired Amnis and Guava businesses, expanding its reach across cell analysis workflows. The company serves life science researchers and clinical laboratories with solutions used in areas such as immunology, cancer research, infectious disease, and inflammatory disease studies. Headquartered in Fremont, California, Cytek Biosciences focuses on providing a comprehensive platform for cell analysis in global research and applied science markets.

CEO Dr. Wenbin Jiang Ph.D. · 682 employees · United States · https://cytekbio.com